You have free access to this content

Cancer

Cover image for Cancer

1 February 2007

Volume 109, Issue 3

Pages 455–643

  1. Review Articles

    1. Top of page
    2. Review Articles
    3. Research Articles
    1. You have free access to this content
      Chemotherapy for metastatic melanoma : Time for a change? (pages 455–464)

      Helen J. Gogas, John M. Kirkwood and Vernon K. Sondak

      Version of Record online: 2 JAN 2007 | DOI: 10.1002/cncr.22427

      The authors reviewed the current status of single-agent and combination chemotherapy in the treatment of melanoma. They also investigated the future prospects for combining chemotherapy with molecularly targeted agents in melanoma.

    2. You have free access to this content
      Provider roles in the recruitment of underrepresented populations to cancer clinical trials (pages 465–476)

      Mollie W. Howerton, M. Chris Gibbons, Charles R. Baffi, Tiffany L. Gary, Gabriel Y. Lai, Shari Bolen, Jon Tilburt, Teerath Peter Tanpitukpongse, Renee F. Wilson, Neil R. Powe, Eric B. Bass and Jean G. Ford

      Version of Record online: 2 JAN 2007 | DOI: 10.1002/cncr.22436

      • original image
      • original image
      • original image

      Results from the analysis provide an initial insight into the provider-related factors involved in the recruitment of underrepresented populations to cancer clinical trials. Future studies should consider including both qualitative and quantitative assessments of provider knowledge, attitudes, and beliefs about clinical trials; the frequency that providers present patients the opportunities to enroll in clinical trials; and the number of patients that are actually eligible for clinical trials.

    3. You have free access to this content
      Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? (pages 477–486)

      William K. Oh, Miah-Hiang Tay and Jiaoti Huang

      Version of Record online: 21 DEC 2006 | DOI: 10.1002/cncr.22439

      Recent studies have demonstrated evidence of activity of platinum chemotherapy in hormone-refractory prostate cancer, including drugs like carboplatin and satraplatin. Neuroendocrine differentiation of prostate cancer may represent an important target for improved therapies.

  2. Research Articles

    1. Top of page
    2. Review Articles
    3. Research Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Underestimation of malignancy of breast core-needle biopsy : Concepts and precise overall and category-specific estimates (pages 487–495)

      Nehmat Houssami, Stefano Ciatto, Ian Ellis and Daniela Ambrogetti

      Version of Record online: 21 DEC 2006 | DOI: 10.1002/cncr.22435

      Based on the largest known evaluation to date (758 eligible women from 4035 consecutive needle biopsies), core-needle biopsy (CNB) underestimation of breast malignancy occurred in 27.7% of CNBs (95% confidence interval [95% CI], 24.5–30.9%) with borderline histology, and underestimation of invasive malignancy occurred in 22.8% of CNBs (95% CI, 19.0–26.5%) with histology that showed DCIS. CNB underestimation of malignancy was associated significantly with greater lesion size on imaging, occurred at the same rate for masses and for calcifications, and occurred less frequently with vacuum-assisted (11-gauge) relative to automated (140-gauge) devices.

    2. You have free access to this content
      Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy (pages 496–501)

      Chafika Mazouni, Angeline Hall, Kristine Broglio, Herbert Fritsche, Fabrice Andre, Francisco J. Esteva, Gabriel N. Hortobagyi, Aman U. Buzdar, Lajos Pusztai and Massimo Cristofanilli

      Version of Record online: 5 DEC 2006 | DOI: 10.1002/cncr.22418

      • original image
      • original image
      • original image
      • original image

      A decrease in serum HER-2 extracellular domain (ECD) levels early in treatment is a predictor of pathological complete response (pCR). Serum HER-2 ECD levels can serve to monitor neoadjuvant therapy in HER-2-positive primary breast cancer.

    3. Chest
      You have free access to this content
      Topoisomerase 2α plays a pivotal role in the tumor biology of stage IV thymic neoplasia (pages 502–509)

      J. M. Liu, L. S. Wang, M. H. Huang, W. H. Hsu, S. H. Yen, C. Y. Shiau, A. F. Y. Li, C. M. Tiu, S. W. Tseng and B. S. Huang

      Version of Record online: 7 DEC 2006 | DOI: 10.1002/cncr.22404

      • original image

      Topoisomerase 2α and Her-2/neu gene amplification and protein overexpression is found in a significant number of advanced thymic neoplasia and its presence impacts tumor biology, chemotherapy response, and patient survival.

    4. Gastrointestinal Tract
      You have free access to this content
      Calcium, dietary, and lifestyle factors in the prevention of colorectal adenomas (pages 510–517)

      Eric A. Miller, Temitope O. Keku, Jessie A. Satia, Christopher F. Martin, Joseph A. Galanko and Robert S. Sandler

      Version of Record online: 2 JAN 2007 | DOI: 10.1002/cncr.22453

      Stronger inverse associations between calcium and the prevalence of adenomas were found among patients with lower fat intake and regular use of nonsteroidal antiinflammatory drugs (NSAIDs). The data suggest that a lower-fat diet and regular NSAID use may enhance calcium's effectiveness as a colorectal cancer preventive agent.

    5. Genitourinary Disease
      You have free access to this content
      Cumulative cost pattern comparison of prostate cancer treatments (pages 518–527)

      Leslie S. Wilson, Ross Tesoro, Eric P. Elkin, Natalia Sadetsky, Jeanette M. Broering, David M. Latini, Janeen DuChane, Reema R. Mody and Peter R. Carroll

      Version of Record online: 21 DEC 2006 | DOI: 10.1002/cncr.22433

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Expenses for prostate cancer treatment are high ($42,570 over a span of 5 years) and vary across treatments, even when age and disease stage are statistically controlled to reflect appropriateness of care according to clinical treatment guidelines. Comparing cumulative costs over time is more accurate than comparing short-term costs.

    6. You have free access to this content
      Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors (pages 528–535)

      Scott E. Eggener, Brett S. Carver, Stacy Loeb, G. Varuni Kondagunta, George J. Bosl and Joel Sheinfeld

      Version of Record online: 18 DEC 2006 | DOI: 10.1002/cncr.22440

      • original image

      Retroperitoneal lymph node dissection after multiple chemotherapy regimens resulted in excellent disease-specific survival. Patients who received taxane-based salvage chemotherapy regimens appeared to have lower rates of viable germ cell tumor at surgery.

    7. You have free access to this content
      Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy (pages 536–541)

      Michael F. Sarosdy

      Version of Record online: 20 DEC 2006 | DOI: 10.1002/cncr.22438

      The objective of this study was to assess the risk of biochemical failure with testosterone-replacement therapy (TRT) after treatment of early prostate cancer with permanent transperineal brachytherapy with or without external beam therapy in patients with low serum levels of testosterone and clinical symptoms of hypogonadism. The results indicated that, for patients with low serum testosterone levels and symptoms of hypogonadism, TRT may be used with caution and close follow-up after prostate brachytherapy.

    8. You have free access to this content
      Factors affecting outcomes after radical cystectomy in African Americans (pages 542–548)

      Badrinath R. Konety, Veerasathpurush Allareddy and Peter R. Carroll

      Version of Record online: 2 JAN 2007 | DOI: 10.1002/cncr.22449

      The authors investigated the association between race and hospital volume as a possible explanation for the observed racial differences in outcomes after radical cystectomy for bladder cancer. When the analyses were controlled for multiple patient and hospital level factors, the results indicated that African Americans with bladder cancer tend to undergo cystectomy at low-volume hospitals, and they also have a greater likelihood of experiencing postcystectomy complications and longer hospital stays.

    9. You have free access to this content
      Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function (pages 549–555)

      Matthew D. Galsky, Alexia Iasonos, Svetlana Mironov, Joseph Scattergood, Mary G. Boyle and Dean F. Bajorin

      Version of Record online: 2 JAN 2007 | DOI: 10.1002/cncr.22454

      • original image

      Cisplatin-based therapy is standard in patients with advanced urothelial carcinoma but a large proportion are ineligible due to renal impairment. The safety and activity of a dose-dense carboplatin-based regimen in this patient population were explored.

    10. Gynecologic Oncology
      You have free access to this content
      Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-α, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma (pages 556–565)

      Henry J.M.A.A. Zijlmans, Gert Jan Fleuren, Hans J. Baelde, Paul H.C. Eilers, Gemma G. Kenter and Arko Gorter

      Version of Record online: 18 DEC 2006 | DOI: 10.1002/cncr.22428

      • original image
      • original image
      • original image

      GM-CSF, TNF-α, and IL-12 are produced by cervical carcinoma cells. These cytokines are involved in activity, differentiation, and migration of antigen-presenting cells. The article describes the expression level of GM-CSF, TNF-α, and IL-12 and their relation with the location of different types of antigen-presenting cells and survival.

    11. Head and Neck Disease
      You have free access to this content
      Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy (pages 566–573)

      Rahul R. Parikh, Qifeng Yang and Bruce G. Haffty

      Version of Record online: 20 DEC 2006 | DOI: 10.1002/cncr.22432

      • original image
      • original image

      VEGF expression was evaluated in a cohort of T1-T2 N0 larynx cancer patients treated with radiation therapy. VEGF expression correlated with overall survival but not with local relapse.

    12. Lung Disease
      You have free access to this content
      8-Hydroxy-2′-deoxyguanosine (8-OH-dG) as a potential survival biomarker in patients with nonsmall-cell lung cancer (pages 574–580)

      Jie Shen, Prescott Deininger, Jay D. Hunt and Hua Zhao

      Version of Record online: 7 DEC 2006 | DOI: 10.1002/cncr.22417

      • original image
      • original image
      • original image

      Nonsmall-cell lung cancer patients with low levels of 8-OH-dG had significantly longer survival times compared with those with high levels of 8-OH-dG. In Cox regression analysis, patients with high levels of 8-OH-dG had an over 3-fold increased hazard of death.

    13. You have free access to this content
      Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung (pages 581–587)

      Shin Myung Kang, Hyun Ju Kang, Ju Hye Shin, Hoguen Kim, Dong Hwan Shin, Se Kyu Kim, Joo-Hang Kim, Kyung Young Chung, Sung Kyu Kim and Joon Chang

      Version of Record online: 21 DEC 2006 | DOI: 10.1002/cncr.22413

      • original image

      The frequency of EGFR mutations and clinicopathologic characteristics of the EGFR mutants in adenosquamous carcinoma are similar to those of Asian patients with adenocarcinomas. Identical EGFR mutations in adenocarcinomatous and squamous cell carcinomatous components suggest the possibility of monoclonality in the histogenesis of adenosquamous carcinoma.

    14. Neuro-Oncology
      You have free access to this content
      Celecoxib inhibits meningioma tumor growth in a mouse xenograft model (pages 588–597)

      Brian T. Ragel, Randy L. Jensen, David L. Gillespie, Stephen M. Prescott and William T. Couldwell

      Version of Record online: 18 DEC 2006 | DOI: 10.1002/cncr.22441

      • original image
      • original image
      • original image
      • original image
      • original image

      Celecoxib inhibits meningioma growth in vivo at plasma levels achievable in humans. COX-2 inhibitors may have a role in the treatment of recurrent meningiomas.

    15. Sarcoma
      You have free access to this content
      Periosteal margin in soft-tissue sarcoma (pages 598–602)

      Patrick P. Lin, Eduardo Diaz Pino, Anne N. Normand, Michael T. Deavers, Christopher P. Cannon, Matthew T. Ballo, Peter W.T. Pisters, Raphael E. Pollock, Valerae O. Lewis, Gunar K. Zagars and Alan W. Yasko

      Version of Record online: 20 DEC 2006 | DOI: 10.1002/cncr.22429

      • original image
      • original image

      Fifty patients with deep, high-grade, T2 soft-tissue sarcomas abutting bone were analyzed retrospectively for recurrence in bone. The periosteum is an adequate margin in the large majority of cases, and composite bone/soft-tissue resections are recommended only for frank bone invasion.

    16. You have free access to this content
      Chemotherapy response is an important predictor of local recurrence in ewing sarcoma (pages 603–611)

      Patrick P. Lin, Norman Jaffe, Cynthia E. Herzog, Colleen M. Costelloe, Michael T. Deavers, Jeana S. Kelly, Shreyaskumar R. Patel, John E. Madewell, Valerae O. Lewis, Christopher P. Cannon, Robert S. Benjamin and Alan W. Yasko

      Version of Record online: 18 DEC 2006 | DOI: 10.1002/cncr.22412

      • original image
      • original image
      • original image

      A retrospective analysis of 64 patients with Ewing sarcoma was performed to determine prognostic factors contributing to local recurrence after surgical treatment. The response to chemotherapy as determined by the amount of tumor necrosis in the resected specimen was found to have a significant correlation with local recurrence.

    17. Discipline

      Cancer Disparities
      You have free access to this content
      Racial differences in tumor stage and survival for colorectal cancer in an insured population (pages 612–620)

      Chyke A. Doubeni, Terry S. Field, Diana S.M. Buist, Eli J. Korner, Carol Bigelow, Lois Lamerato, Lisa Herrinton, Virginia P. Quinn, Gene Hart, Mark C. Hornbrook, Jerry H. Gurwitz and Edward H. Wagner

      Version of Record online: 21 DEC 2006 | DOI: 10.1002/cncr.22437

      • original image

      The results from this study indicated the presence of complex racial disparities for colorectal cancer in patients who received care in integrated health care systems despite the availability of health insurance and the potential for a regular source of preventive health care. The disparities in survival were related to differences in tumor stage and the receipt of cancer-related therapies but did not appear to be related to differences in comorbidity.

    18. Medical Oncology
      You have free access to this content
      Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes (pages 621–627)

      Mona G. Sarkiss, S. Wamique Yusuf, Carla L. Warneke, Gregory Botz, Nasser Lakkis, Cheryl Hirch-Ginsburg, J. Chris Champion, Joseph Swafford, Andrew D. S. Shaw, Daniel J. Lenihan and Jean-Bernard Durand

      Version of Record online: 13 DEC 2006 | DOI: 10.1002/cncr.22434

      • original image
      • original image
      • original image

      Aspirin therapy in cancer patients with acute coronary syndrome significantly reduces mortality especially in the setting of thrombocytopenia, a new platelet paradox.

    19. Radiation Oncology
      You have free access to this content
      Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery (pages 628–636)

      Samuel Ryu, Jian-Yue Jin, Ryan Jin, Jack Rock, Munther Ajlouni, Benjamin Movsas, Mark Rosenblum and Jae Ho Kim

      Version of Record online: 13 DEC 2006 | DOI: 10.1002/cncr.22442

      • original image
      • original image
      • original image
      • original image
      • original image

      Because of the rapid dose fall-off within the spinal cord by spine radiosurgery, partial volume tolerance dose of the spinal cord was analyzed. The average dose to the 10% spinal cord volume was 9.8 ± 1.5 Gy in the group of 18 Gy prescribed dose. Among the 86 patients >1 year survival, there was 1 case of radiation-induced cord injury after 13 months of radiosurgery. There were no other cases of spinal cord sequelae. Partial volume spinal cord tolerance is at least 10 Gy to 10% of the spinal cord volume defined as 6 mm above and below the radiosurgery target.

    20. Symptom Control and Palliative Care
      You have free access to this content
      Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain (pages 637–643)

      Oliver Sartor, Robert H. Reid, David L. Bushnell, Donald P. Quick and Peter J. Ell

      Version of Record online: 13 DEC 2006 | DOI: 10.1002/cncr.22431

      • original image
      • original image

      Repeated dosing of 1.0 mCi/kg of samarium Sm 153 lexidronam was both effective and well tolerated and can be considered a reasonable treatment option in patients whose bone pain responds and then recurs after an initial dose, provided that adequate hematologic function is present at the time of drug administration.

SEARCH

SEARCH BY CITATION